Biomarkers Products & Reviews

1 x 96-well, includes coupled magnetic beads, detection antibodies, standards, reagents, and diluents for detecting 23 mouse cytokines all in one kit

1 x 96-well, includes coupled magnetic beads, detection antibodies, standards, reagents, and diluents for detecting 9 mouse cytokines all in one kit

Magnetic bead–based assays for the detection and measurement of 46 mouse cytokines, chemokines, and growth factors. Available as premixed assay panels, singleplex sets, or as custom x-Plex™ and Express Assays.

Novel Coronavirus 2019-nCoV (SARS-CoV-2) Spike Glycoprotein (S1) is a recombinant antigen which contains the Spike protein amino acids 1-674. Spike S1 protein is manufactured in HEK293 mammalian cells, ensuring the most authentic post-translational modifications.

Novel Coronavirus 2019-nCoV (SARS-CoV-2) Spike Glycoprotein (S2) is a recombinant antigen which contains the Spike S2 protein, amino acids 685-1211. Spike S2 is manufactured in mammalian HEK293 cells to ensure the most authentic post-translational modifications.

The Native Antigen Company offers a selection of complementary easy-to-use antibody conjugation formats, with a wide range of labels suitable for use in most applications. On request we can also undertake custom conjugation of proteins and antibodies.

With decades of experience in the field of native antigen and recombinant protein production, and assay development, The Native Antigen Company is able to undertake a wide range of custom projects on your behalf.  

SARS-CoV-2 Nucleoprotein is a recombinant antigen manufactured in E. coli cells to high purity for use in vaccine research and immunoassay development. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

SARS-CoV-2 Spike Glycoprotein (S2) is a recombinant antigen which contains the Spike protein amino acids 685-1211 of subunit 2. Spike S2 protein is manufactured to high yield and purity using the Native Antigens baculovirus-insect cell platform. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

SARS-CoV-2 Spike-E-M Mosaic protein is a recombinant antigen manufactured in E. coli with greater than 95% purity, and containing the Spike (S), Envelope (E) and Membrane (M) immunodominant regions. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

Human Coronavirus 229E Nucleoprotein is a recombinant protein containing 359 amino acids derived from the nucleocapsid sequence, with a C-terminal 6xHis tag. It is manufactured in E. coli with greater than 95% purity.

Human Coronavirus NL63 Nucleoprotein is a recombinant protein containing the nucleocapsid C-terminal region (130 amino acids), cloned and expressed in E. coli, and purified by affinity chromatography (nickel column) with greater than 95% purity.

The most comprehensive, high-performance protein biomarker panel available for inflammation studies.

Together with our Neuro Exploratory panel, this provides the most comprehensive, high-performance protein biomarker solution available for neurological disease studies.

CIL has been manufacturing amino acid standards and carnitine/acylcarnitine standards calibration standards for over 15 years. We offer both 10-vial sets or single vials of these products. 

The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is a serological, multiplexed microsphere-based assay to measure the presence of IgG antibodies directed against the nucleocapsid protein (N), Receptor-Binding Domain (RBD) of the spike protein, and the S1 subunit of the spike protein (S1) of SARS-CoV-2 in human serum or plasma. The xMAP SARS-CoV-2 Multi-Antigen IgG Assay features: Broad Coverage: Detects IgG antibodies aga…

Tissue Solutions is a leading global provider of ethically sourced human tissue samples used in all areas of drug discovery, research and development. ISO 9001:2015 certified and twice winner of the coveted Queens Award for Enterprise, Tissue Solutions offer a single point of access for a wide range of diseased and normal tissues in fresh, frozen, and FFPE formats.

HistologiX is a leading GLP/GCP accredited Contract Research Organisation based in the UK specialising in Histology, Immunohistochemistry (IHC) and Digital Pathology services. HistologiX works with a broad range of clients from big pharma to small and medium biotech companies worldwide. Our team of scientists have in excess of 120 years combined experience and a customer retention rate of 80%. 

HistologiX is a leading GLP/GCP accredited Contract Research Organisation based in the UK specialising in Histology, Immunohistochemistry (IHC) and Digital Pathology services. HistologiX works with a broad range of clients from big pharma to small and medium biotech companies worldwide. Our team of scientists have in excess of 120 years combined experience and a customer retention rate of 80%. 

Reliable in vivo breath sample collection of VOCs and respiratory droplets for biomarker identification and validation. Suitable for use in a range of contexts and diverse applications including early detection, drug development and precision medicine for conditions including respiratory diseases, liver diseases and cancer. Compatible with a range of analytical systems including GC-MS analysis with Breath Biopsy Services.

Combining high resolution accurate mass mass spectrometry and world-leading breath analysis expertise to offer complete breath biomarker discovery and validation solutions. Breath Biopsy Services provide versatile Breath Biopsy sample analysis and reporting driven by GC-Orbitrap technology and supported by a rigorous quality assurance process ensuring reliable, high sensitivity VOC biomarker detection.

Exogenous volatile organic compound probes (EVOC Probes) enable targeted, non-invasive assessment of biological pathways. Probes are safe, easy to administer compounds that interact with characterised metabolic pathways with relevance to key disease areas. Using Breath Biopsy, EVOC Probes can be monitored non-invasively on breath, either alone or in parallel with biomarker discovery studies.

A targeted panel of compounds with established relevance for respiratory diseases enabling high confidence, non-invasive disease detection and monitoring. Each compound is supported by evidence from breath research studies of relevant respiratory diseases and disease processes. The panel is available as an aspect of Breath Biopsy Services and panels for other disease applications are in development.

Identify prospective biomarkers relevant to key disease processes through in vitro GC-MS analysis. Compatible with headspace sampling from cell cultures, macromolecular preparations and ex vivo samples. Driven by GC-Orbitrap high-resolution mass spectrometry and supported by a rigorous and comprehensive quality assurance process. Results are suitable for comparison with in vivo studies using Breath Biopsy Services.

Consumable components of the Breath Biopsy system, required for robust breath sample collection using the ReCIVA Breath Sampler as part of the Breath Biopsy Collection Station. One Kit per sample.